Search Results

Site Search

Comprehensive drug urine profiles - Insights

Able to detect 22 drug classes, our comprehensive addiction medicine profile can help identify polysubstance use disorder as well as assess and manage patients at risk for substance use disorder.

The Value Stream of an Outreach Program - Insights

When considering the outreach laboratory value stream, it is important to remember that without quality, there is no value. Through identifying sources for error or non-value-added activities, the hospital laboratory outreach program can...

What the Patient Considers When Choosing a Laboratory - Insights

Patients want to use a laboratory that is easy to work with, and there are different definitions of “easy.” Ultimately, health systems want to have the patients they serve use their health system laboratories. If patients are choosing to go...

Is the term "outreach" obsolete? - Insights

In a competitive outpatient testing market, choosing a laboratory is discretionary. With the goal of becoming the laboratory of choice for discretionary outpatient testing, it no longer matters if it is called “inreach” or “outreach.” While...

Tests aid diagnosis of primary biliary cholangitis: Anne Tebo, Ph.D. - Insights

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune...

Mayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnostics - Insights

Mayo Clinic Laboratories and Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the...

Drug class testing - Insights

Check out Mayo Clinic Laboratories’ full menu of testing for individual drug classes, including benzodiazepines, stimulants, opioids, alcohol, and more.

Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services - Insights

Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to...

New tests launched in February - Insights

In February 2023, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

New tests launched in February - Insights

In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.